BCS vs BK

Barclays PLC (BCS) exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant fundamental deterioration. Despite strong recent price performance and a low forward P/E of 8.96, the stock trades above both the Graham Number ($17.26) and intrinsic value estimate ($15.26), suggesting overvaluation. Profitability margins are strong, but ROA is extremely low at 0.44%, and earnings growth is negative both year-over-year and quarter-over-quarter. Combined with bearish insider activity and weak technical trend scores, the risk-reward profile is unattractive.

BK exhibits stable financial health with a Piotroski F-Score of 4/9 and an exceptional operational track record, beating earnings estimates in nearly every quarter over the last 25 periods. While the current price of $131.96 trades at a premium to the Graham Number ($97.73), it remains significantly discounted relative to its growth-based intrinsic value of $218.3. Strong YoY earnings growth of 30.5% and a conservative dividend payout ratio of 27.03% suggest sustainable long-term expansion. The primary divergence is a bearish technical trend score despite strong recent price performance.